177 related articles for article (PubMed ID: 37789648)
1. Immunomodulatory effects of intravenous and subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: An observational study.
Svačina MKR; Meißner A; Schweitzer F; Ladwig A; Pitarokoili K; Kofler DM; Sprenger-Svačina A; Schneider C; Kohle F; Klein I; Wüstenberg H; Lehmann HC
Eur J Neurol; 2024 Jan; 31(1):e16079. PubMed ID: 37789648
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.
Markvardsen LH; Sindrup SH; Christiansen I; Olsen NK; Jakobsen J; Andersen H;
Eur J Neurol; 2017 Feb; 24(2):412-418. PubMed ID: 28000311
[TBL] [Abstract][Full Text] [Related]
3. Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin.
Vu T; Anthony N; Alsina R; Harvey B; Schleutker A; Farias J; Dang S; Suresh N; Gooch C
Muscle Nerve; 2021 Sep; 64(3):351-357. PubMed ID: 34076265
[TBL] [Abstract][Full Text] [Related]
4. CIDP: Analysis of Immunomarkers During COVID-19 mRNA-Vaccination and IVIg-Immunomodulation: An Exploratory Study.
Svačina MKR; Meißner A; Schweitzer F; Sprenger-Svačina A; Klein I; Wüstenberg H; Kohle F; Walter HL; Schroeter M; Lehmann HC
J Neuroimmune Pharmacol; 2023 Jun; 18(1-2):208-214. PubMed ID: 36929282
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
[TBL] [Abstract][Full Text] [Related]
6. Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.
Markvardsen LH; Christiansen I; Jakobsen J
Transfusion; 2016 Oct; 56(10):2443-2448. PubMed ID: 27401495
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy.
Goyal NA; Karam C; Sheikh KA; Dimachkie MM
Muscle Nerve; 2021 Sep; 64(3):243-254. PubMed ID: 34260074
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy.
Lee DH; Linker RA; Paulus W; Schneider-Gold C; Chan A; Gold R
Muscle Nerve; 2008 Mar; 37(3):406-9. PubMed ID: 17918749
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of subcutaneous versus intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy: a real-life study.
Piscitelli E; Massa M; De Martino BM; Serio CS; Guglielmi G; Colacicco G; Tuccillo F; Habetswallner F
Eur J Hosp Pharm; 2021 Nov; 28(Suppl 2):e115-e119. PubMed ID: 33122403
[TBL] [Abstract][Full Text] [Related]
10. Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?
Allen JA; Gelinas DF; Freimer M; Runken MC; Wolfe GI
J Neurol Sci; 2020 Jan; 408():116497. PubMed ID: 31765922
[TBL] [Abstract][Full Text] [Related]
11. Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin.
Cirillo G; Todisco V; Tedeschi G
Clin Neurophysiol; 2018 May; 129(5):967-973. PubMed ID: 29554579
[TBL] [Abstract][Full Text] [Related]
12. Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years.
Gentile L; Mazzeo A; Russo M; Arimatea I; Vita G; Toscano A
Sci Rep; 2020 May; 10(1):7910. PubMed ID: 32404895
[TBL] [Abstract][Full Text] [Related]
13. Changes in axonal and clinical function during intravenous and subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy.
Hansen PN; Mohammed AA; Markvardsen LK; Andersen H; Tankisi H; Sindrup SH; Krøigård T
J Peripher Nerv Syst; 2023 Sep; 28(3):425-435. PubMed ID: 37212187
[TBL] [Abstract][Full Text] [Related]
14. IgPro20, the Polyneuropathy and Treatment with Hizentra
Berger M; Harbo T; Cornblath DR; Mielke O
Immunotherapy; 2018 Aug; 10(11):919-933. PubMed ID: 29764262
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis.
Lazzaro C; Lopiano L; Cocito D
Neurol Sci; 2014 Jul; 35(7):1023-34. PubMed ID: 24469345
[TBL] [Abstract][Full Text] [Related]
16. A new treatment regimen with high-dose and fractioned immunoglobulin in a special subgroup of severe and dependent CIDP patients.
Debs R; Reach P; Cret C; Demeret S; Saheb S; Maisonobe T; Viala K
Int J Neurosci; 2017 Oct; 127(10):864-872. PubMed ID: 27918219
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy.
Markvardsen LH; Harbo T; Sindrup SH; Christiansen I; Andersen H; Jakobsen J;
Eur J Neurol; 2014 Dec; 21(12):1465-70. PubMed ID: 25041191
[TBL] [Abstract][Full Text] [Related]
18. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.
Oaklander AL; Lunn MP; Hughes RA; van Schaik IN; Frost C; Chalk CH
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010369. PubMed ID: 28084646
[TBL] [Abstract][Full Text] [Related]
19. Switch from intravenous to subcutaneous immunoglobulin IgPro20 in CIDP patients: a prospective observational study under real-world conditions.
Gingele S; Koch M; Saparilla AC; Körner GM; von Hörsten J; Gingele M; Seeliger T; Konen FF; Hümmert MW; Neyazi A; Stangel M; Skripuletz T
Ther Adv Neurol Disord; 2021; 14():17562864211009100. PubMed ID: 33948119
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy.
Markvardsen LH; Debost JC; Harbo T; Sindrup SH; Andersen H; Christiansen I; Otto M; Olsen NK; Lassen LL; Jakobsen J;
Eur J Neurol; 2013 May; 20(5):836-42. PubMed ID: 23294032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]